SB590885 is primarily used in research settings as a selective inhibitor of BRAF kinase, particularly targeting the V600E mutation. This mutation is commonly found in various cancers, including melanoma. By inhibiting BRAF V600E, SB590885 helps researchers study the pathways involved in cancer cell proliferation and survival. It is a valuable tool for understanding the mechanisms of BRAF-driven cancers and for evaluating potential therapeutic strategies. Additionally, SB590885 is utilized in preclinical studies to assess the efficacy of BRAF inhibition in combination with other targeted therapies, aiding in the development of more effective cancer treatments.